Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

Over the years, the Pittsburgher has been dubbed as the “Super Bowl” of super late model dirt racing in Western Pa. The race has held local importance, but on Saturday, the 35th annual competition at ...

In a retrospective, real-world cohort study, the factors complicating the diagnosis of primary progressive forms of multiple sclerosis (PPMS) were explored. In a study published in the European ...

Multiple sclerosis (MS) is a neurological disease that causes symptoms like fatigue, impaired mobility, and speech issues. The most common types are RRMS or PPMS, each with different symptom timing ...

Deep learning identified subgroups of patients with primary progressive multiple sclerosis (PPMS) who may respond to disease-modifying therapy, researchers said. A trained model separated responders ...

Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what’s true (and what’s not) can help you feel ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Early, ...

As independent auto dealers look to bolster their competitiveness and strengthen their performance, many are turning to practices franchised dealers have been using for some time to increase their ...

Primary progressive multiple sclerosis (PPMS) is an uncommon form of MS that affects approximately 10-15% of MS patients. In PPMS, symptoms steadily get worse over time without frequent relapses or ...

Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...